1-3 of 3
Joshua Boss, RN, OCN
Close
Sort by
Journal Articles

Early Immune Reconstitution after Haplo-Identical Hematopoietic Stem Cell Transplantation (HCT) with Post-Transplant Cyclophosphamide (PTCY) Does Not Improve Overall Survival Compared to Matched Unrelated Donor HCT Recipients Receiving Thymoglobulin Prophylaxis (ATG)

Yasser Khaled, MD, Joshua Boss, RN, OCN, BMTCN, Poojitha Valasareddy, MD, Arnel Pallera, MD, Robert Johnson, MD, Deniscer Peeler, LPN, Jason C. Chandler, MD, Joel Gradowski, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5676.
https://doi.org/10.1182/blood-2019-131954
Published: 2019
Journal Articles

Improved Relapse Rate, T Cell Recovery and Engraftment in High Risk Hematological Malignancies with Enhanced Lympho-Depletion Prior to T-Cell Replete Peripheral Blood Haploidentical (HID) Hematopoietic Stem Cell Transplantation (HCT)

Yasser Khaled, MD, Joshua Boss, RN, OCN, BMTCN, Joel Gradowski, MD, Robert Bradley, MD, Jason C. Chandler, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2117.
https://doi.org/10.1182/blood-2018-99-115290
Published: 2018
Journal Articles

T-Cell Replete Peripheral Blood Haploidentical Transplant Using Immunogenic Dose of Cyclophosphamide with Fludarabine and Melphalan Results in Enhanced Cytokine Release Syndrome (CRS) with Robust Immune Recovery and Low Relapse Rates

Yasser Khaled, MD, Jason C. Chandler, MD, Joshua Boss, RN, OCN, Arnel Pallera, MD, Michael G. Martin, MD, Robert Bradley, MD, Robert Johnson, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1934.
https://doi.org/10.1182/blood.V130.Suppl_1.1934.1934
Published: 2017